Evidence map›Paper›PMID 37858159›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.

Brittney S Harrington, Rahul Kamdar, Franklin Ning, Soumya Korrapati, Michael W Caminear, Lidia F Hernandez, Donna Butcher, Elijah F Edmondson, Nadia Traficante, Joy Hendley and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Uridine as a hub in cancer metabolism and RNA biology.Experimental & molecular medicine · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 2 countries.

Brittney S HarringtonWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0001-7083-069X
Rahul KamdarWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Franklin NingWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Soumya KorrapatiWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Michael W CaminearWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Lidia F HernandezWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Donna ButcherMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, NCI, Frederick, MD, 21702, USA.
Elijah F EdmondsonMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, NCI, Frederick, MD, 21702, USA.
Nadia TraficantePeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Joy HendleyPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Australian Ovarian Cancer Study
Madeline GoughMater Brisbane Hospital, Mater Health Services, South Brisbane, QLD, 4101, Australia.
Rebecca RogersMater Brisbane Hospital, Mater Health Services, South Brisbane, QLD, 4101, Australia.
Rohan LourieMater Brisbane Hospital, Mater Health Services, South Brisbane, QLD, 4101, Australia.
Jyoti ShettyCCR Sequencing Facility, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, USA.
Bao TranCCR Sequencing Facility, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, USA.
Fathi ElloumiCollaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Abdalla AbdelmaksoudCollaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Madhu Lal NagCollaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Krystyna Mazan-MamczarzFunctional Genomics Lab, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, 20892, USA.
Carrie D HouseWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
John D HooperMater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD, 4102, Australia.
Christina M AnnunziataWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. christina.annunziata@cancer.org.
National Institutes of Health · USLeidos (United States) · USFrederick National Laboratory for Cancer Research · USMater Health Services · AUThe University of Melbourne · AUNational Cancer Institute · USTranslational Research Institute · AU

Funding

Nuclear Factor-kappaB in Ovarian CancerZIABC011054 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ANNUNZIATA, CHRISTINA · 2009 to 2023
$12.1M
Intramural NIH HHS ZIA BC011054NCI NIH HHS HHSN261201800001CNCI NIH HHS ZIA BC011054NIH HHS HHSN261200800001ENIH HHS HHSN261201800001I
6 · The paper itself

Abstract

backgroundEpithelial ovarian cancer (EOC) is a global health burden, with the poorest five-year survival rate of the gynecological malignancies due to diagnosis at advanced stage and high recurrence rate. Recurrence in EOC is driven by the survival of chemoresistant, stem-like tumor-initiating cells (TICs) that are supported by a complex extracellular matrix and immunosuppressive microenvironment. To target TICs to prevent recurrence, we identified genes critical for TIC viability from a whole genome siRNA screen. A top hit was the cancer-associated, proteoglycan subunit synthesis enzyme UDP-glucose dehydrogenase (UGDH).

methodsImmunohistochemistry was used to characterize UGDH expression in histological and molecular subtypes of EOC. EOC cell lines were subtyped according to the molecular subtypes and the functional effects of modulating UGDH expression in vitro and in vivo in C1/Mesenchymal and C4/Differentiated subtype cell lines was examined.

resultsHigh UGDH expression was observed in high-grade serous ovarian cancers and a distinctive survival prognostic for UGDH expression was revealed when serous cancers were stratified by molecular subtype. High UGDH was associated with a poor prognosis in the C1/Mesenchymal subtype and low UGDH was associated with poor prognosis in the C4/Differentiated subtype. Knockdown of UGDH in the C1/mesenchymal molecular subtype reduced spheroid formation and viability and reduced the CD133 + /ALDH

conclusionsThese data show that modulation of UGDH expression in ovarian cancer reveals distinct roles for UGDH in the C1/Mesenchymal and C4/Differentiated molecular subtypes of EOC, influencing the tumor microenvironmental composition. UGDH is a strong potential therapeutic target in TICs, for the treatment of EOC, particularly in patients with the mesenchymal molecular subtype.

Indexed as

Carcinoma, Ovarian EpithelialOvarian NeoplasmsTumor MicroenvironmentUridine Diphosphate Glucose DehydrogenaseAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMicePrognosisRNA, Small InterferingRNA, Small InterferingUGDH protein, humanUridine Diphosphate Glucose DehydrogenaseMesenchymalMolecular subtypesOvarian cancerTumor microenvironmentUGDH

Identifiers

PMID37858159
PMCPMC10585874
OpenAlexW4387780175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.